Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Skin cream for rare facial bumps shows promise but study halted early

NCT ID NCT03363763

First seen Dec 18, 2025 · Last updated May 23, 2026 · Updated 20 times

Summary

This study tested a sirolimus cream (0.2% and 0.4%) applied daily for 12 weeks to treat facial bumps (angiofibromas) in children aged 2-21 with tuberous sclerosis complex. The goal was to see if the cream could safely reduce the bumps. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Children's Clinical Research Organization, Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30329, United States

  • Children's Hospital of Fudan University

    Shanghai, 201102, China

  • Children's Hospital of Los Angeles, Division of Neurology

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • LeBonheur Children's Hospital

    Memphis, Tennessee, 38103, United States

  • Translational Genomics Research

    Phoenix, Arizona, 85004, United States

Conditions

Explore the condition pages connected to this study.